Purpose: We tried to establish the predictive factors influencing the initial response, as well as its duration, and time to castration resistance (CR) for primary advanced prostate cancer (PC) with bone metastasis. Methods: We evaluated all patients initially receiving androgen deprivation therapy (ADT) for primary advanced PC with bone metastasis. A total of 982 patients with complete medical records available for analysis from 18 centers were included in this study. Age, initial PSA, Gleason score (GS) and extent of bone involvement (EBI) were recorded in a database. Results: Among all the patients, 896 (91.2%) responded to ADT initially. Pretreatment PSA and EBI were significant predictors in the multivariate model. Among the 659 patien...
Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sen...
<p>Continuous values are given as median (min-max values).</p>a<p>Castration-resistant patients had ...
BACKGROUND: Few studies have examined the risk of developing castration-resistant prostate cancer (C...
WOS: 000299861400005PubMed ID: 22179324Purpose: We tried to establish the predictive factors influen...
Background: The purpose of this study was to identify the predictive factors for the efficacy of and...
ObjectiveTo investigate predictors of time to metastasis among men treated with androgen deprivation...
To build a practical model for predicting the progression to castration-resistant prostate cancer (C...
Contains fulltext : 173187.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
BACKGROUND: Abiraterone and enzalutamide are 2 novel androgen receptor (AR)-targeting therapies that...
Background: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolvin...
BACKGROUND: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolvi...
Approximately 15% of men with hormone naive metastatic prostate cancer primarily fail to respond to ...
Purpose: We sought to evaluate predictors of overall survival following progression after systemic c...
Purpose: Prostate-specific antigen (PSA) is a surrogate marker of disease progression; however, its ...
PURPOSE: Contemporary treatment for metastatic hormone sensitive prostate cancer (mHSPC) includes an...
Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sen...
<p>Continuous values are given as median (min-max values).</p>a<p>Castration-resistant patients had ...
BACKGROUND: Few studies have examined the risk of developing castration-resistant prostate cancer (C...
WOS: 000299861400005PubMed ID: 22179324Purpose: We tried to establish the predictive factors influen...
Background: The purpose of this study was to identify the predictive factors for the efficacy of and...
ObjectiveTo investigate predictors of time to metastasis among men treated with androgen deprivation...
To build a practical model for predicting the progression to castration-resistant prostate cancer (C...
Contains fulltext : 173187.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
BACKGROUND: Abiraterone and enzalutamide are 2 novel androgen receptor (AR)-targeting therapies that...
Background: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolvin...
BACKGROUND: Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolvi...
Approximately 15% of men with hormone naive metastatic prostate cancer primarily fail to respond to ...
Purpose: We sought to evaluate predictors of overall survival following progression after systemic c...
Purpose: Prostate-specific antigen (PSA) is a surrogate marker of disease progression; however, its ...
PURPOSE: Contemporary treatment for metastatic hormone sensitive prostate cancer (mHSPC) includes an...
Background: To evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sen...
<p>Continuous values are given as median (min-max values).</p>a<p>Castration-resistant patients had ...
BACKGROUND: Few studies have examined the risk of developing castration-resistant prostate cancer (C...